As there are no effective treatments to date, identifying individuals with an increased risk to develop Alzheimer’s disease (AD) might allow disease prevention and onset delay strategies. It was established that the systemic immune system has a crucial role in maintaining healthy brain function and repair. Therefore, it is possible that early clinical conditions affecting systemic immunity may contribute to the onset of AD.
Our approach includes evaluation of conditions/symptoms that are significantly different between control and Alzheimer’s patients before diagnosis. We aim to stratify symptoms that seem to reflect the progression of the disease and those that are associated with increased risk for AD.
Additional analysis will focus on identifying subgroups of patients that were diagnosed with immune-related conditions and see their association to AD. We will also perform a deep investigation of the relation between drugs and AD.